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Therapeutic antidepressant potential of a conjugated siRNA
silencing the serotonin transporter after intranasal
administration
A Ferrés-Coy1,2,3, M Galofré1,2,3, F Pilar-Cuéllar3,4, R Vidal3,4, V Paz1,2,3, E Ruiz-Bronchal1,2,3, L Campa1,2,3, Á Pazos3,4, JR Caso3,5, JC Leza3,5,
G Alvarado6, A Montefeltro6, EM Valdizán3,4, F Artigas1,2,3 and A Bortolozzi1,2,3
Major depression brings about a heavy socio-economic burden worldwide due to its high prevalence and the low efﬁcacy of
antidepressant drugs, mostly inhibiting the serotonin transporter (SERT). As a result, ~ 80% of patients show recurrent or chronic
depression, resulting in a poor quality of life and increased suicide risk. RNA interference (RNAi) strategies have been preliminarily
used to evoke antidepressant-like responses in experimental animals. However, the main limitation for the medical use of RNAi is
the extreme difﬁculty to deliver oligonucleotides to selected neurons/systems in the mammalian brain. Here we show that the
intranasal administration of a sertraline-conjugated small interfering RNA (C-SERT-siRNA) silenced SERT expression/function and
evoked fast antidepressant-like responses in mice. After crossing the permeable olfactory epithelium, the sertraline-conjugated-
siRNA was internalized and transported to serotonin cell bodies by deep Rab-7-associated endomembrane vesicles. Seven-day
C-SERT-siRNA evoked similar or more marked responses than 28-day ﬂuoxetine treatment. Hence, C-SERT-siRNA (i) downregulated
5-HT1A-autoreceptors and facilitated forebrain serotonin neurotransmission, (ii) accelerated the proliferation of neuronal precursors
and (iii) increased hippocampal complexity and plasticity. Further, short-term C-SERT-siRNA reversed depressive-like behaviors in
corticosterone-treated mice. The present results show the feasibility of evoking antidepressant-like responses by selectively
targeting neuronal populations with appropriate siRNA strategies, opening a way for further translational studies.
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INTRODUCTION
Major depressive disorder (MDD) is a severe, chronic and life-
threatening disease with a high incidence; affecting ca. 120 million
people worldwide.1–3 The midbrain serotonin (5-hydroxytrypta-
mine (5-HT)) system has a critical role in many brain functions,
including mood control. Derangements of serotonin pathway are
involved in MDD, and most antidepressant drugs aim to increase
serotonergic function.4 Serotonin transporter (SERT) is a key player
in MDD, by controlling the active 5-HT fraction and, being the
target of most prescribed antidepressant drugs, the selective
serotonin reuptake inhibitors (SSRI) and the selective serotonin and
norepinephrine reuptake inhibitors (SNRI).5,6 These drugs need to
be administered for long time before clinical improvement
emerges, and they fully remit depressive symptoms in only one-
third of patients leaving a large proportion of people with partial or
incomplete clinical responses.7,8 For these reasons, there is an
urgent need to improve antidepressant treatments.
Chronic—but not acute—SSRI treatments elicit a series of
neurobiological changes relevant for antidepressant activity. Hence,
chronic SSRI treatments downregulates SERT, increasing forebrain
serotonergic neurotransmission and neuronal plasticity in the
hippocampus,9–12 although the precise mechanisms involved
remain uncertain. Likewise, chronic SSRI treatments internalize
SERT and reduce SERT-binding sites without affecting SERT mRNA
levels.9,10,13,14 In particular, ﬂuoxetine (FLX) promotes the biogenesis
of microRNA-16, resulting in a downstream repression of SERT
levels in mouse 5-HT neurons, accompanied by antidepressant-like
effects in the chronic mild stress and forced-swim animal models.15
Altogether, these data uncover the functional signiﬁcance
of SERT downregulation in mediating antidepressant responses.
The identiﬁcation of intracellular networks underlying SERT
downregulation may be a new target for the development of
fast-acting antidepressants. Hence, exogenous small interfering
RNAs (siRNAs) have been preliminarily investigated as potential
therapeutic tools to silence the expression of critical genes in 5-HT
neurons.16–18 Intracerebral treatments with siRNA against SERT—or
their related antisense oligonucleotides—signiﬁcantly decreased
SERT expression and function in the rodent brain and evoked
cellular and behavioral responses predictive of clinical antidepres-
sant activity.16,17,19 Despite these exciting prospects, the utility
of RNA interference (RNAi)-based silencing strategies for MDD
treatment is severely compromised by the extreme difﬁculty to
deliver oligonucleotide sequences to their neuronal functional
sites, due to the need to cross several biological barriers after
administration and the evident complexity of the mammalian
brain.20,21
Here we have used targeted delivery of a sertraline
ligand-conjugated siRNA directed against SERT (C-SERT-siRNA) to
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downregulate SERT expression selectively in raphe 5-HT neurons.
We show that C-SERT-siRNA silenced SERT expression/function
and evoked fast and robust antidepressant-like responses after
intranasal (i.n.) administration in mice. Moreover, it reversed the
depressive-like behavior in corticosterone-treated mice due to the
increased 5-HT signaling and synaptic plasticity. These results
highlight the potential of RNAi-based antidepressant therapies
targeting genes linked to antidepressant responses, such as SERT
or the 5-HT1A-autoreceptor
18 through a clinically feasible (i.n.)
administration route.
Figure 1. Selective accumulation of sertraline-conjugated nonsense-siRNA (C-NS-siRNA) in tryptophan hydroxylase2-positive (TPH2-positive)
5-hydroxytryptamine (5-HT) neurons after intranasal administration. Mice were intranasally administered with alexa488 phosphate-buffered
saline (PBS) (A488-PBS) or alexa488-labeled C-NS-siRNA (A488-C-NS-siRNA) at 30 μg day− 1 during 4 days and were killed 6 h
postadministration (n= 2 mice/group). (a) Confocal images showing co-localization of A488-C-NS-siRNA (yellow) in dorsal raphe nucleus
(DR) 5-HT neurons (TPH2-positive, red) identiﬁed with white arrowheads. Cell nuclei were stained with DAPI (4,6-diamidino-2-phenylindole;
blue). Bottom row are high-magniﬁcation photomicrographs of the frames in top row. Scale bars: low= 200 μm, high= 10 μm. (b and c)
Histograms show the distribution proﬁle of the abundance of A488-C-NS-siRNA (expressed as ﬂuorescence units, ranges shown below the
abscissa axis) in TPH2-positive neurons. Note the greater number of TPH2-positive cells co-localized with A488-C-NS-siRNA in the DR compared
with median raphe nucleus (MnR). Range:43, 3–1 and o1 represent relative unit of intracellular A488 density. (d) Number of TPH2-positive
cells in the DR and MnR of mice. AP coordinates (in mm): − 4.24/− 4.36 and − 4.48/− 4.72 from bregma (n= 2 mice/group). *Po0.05,
**Po0.01, ***Po0.001 versus A488-PBS-treated mice. Data are mean± s.e.m.
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MATERIALS AND METHODS
Animals
Male C57BL/6J mice (10–14 weeks; Charles River, Lyon, France) were
housed under controlled conditions (22 ± 1 °C; 12-h light/dark cycle) with
food and water available ad libitum. Animal procedures were conducted in
accordance with standard ethical guidelines (EU regulations L35/118/
12/1986) and approved by the local ethical committee.
Conjugated siRNA synthesis
The synthesis and puriﬁcation of sertraline-conjugated siRNA directed
against SERT (C-SERT-siRNA, nt: 1230–1250, GenBank accession NM_010484)
and sertraline-conjugated nonsense siRNA (C-NS-siRNA) molecules were
performed by nLife Therapeutics S.L. (Granada, Spain).18 Details are shown in
Supplementary Information.
To study in vivo intracellular distribution and incorporation of
conjugated siRNA into 5-HT neurons, C-NS-siRNA was additionally labeled
with alexa488 in the antisense strand (A488-C-NS-siRNA). We used C-NS-
siRNA instead of C-SERT-siRNA to examine the brain distribution after i.n.
administration because C-SERT-siRNA reduces SERT expression (see Results
section), this compromising the penetration of new doses into 5-HT
neurons through SERT. Along these lines, we assumed that the main factor
conferring the neuronal target selectivity was the presence of covalently
bound sertraline rather than the oligonucleotide sequence. Stock solutions
of all siRNAs were prepared in RNAse-free water and stored at − 20 °C until
use. Sequences are shown in Supplementary Table S1.
Treatments
For i.n. administration, mice were slightly anesthetized by 2% isoﬂurane
inhalation and placed in a supine position.18 A 5-μl drop of phosphate-
buffered saline (PBS) or conjugated siRNA (C-NS-siRNA and C-SERT-siRNA)
was applied alternatively to each nostril once daily. A total of 10 μl of
solution containing 30 μg (2.1 nmol day− 1) of conjugated siRNA was
delivered for 1, 4 or 7 days, and mice were killed at 1, 3, 7 or 15 days after
last administration. To evaluate the C-SERT-siRNA efﬁcacy on SERT
knockdown, mice were i.n. treated with the C-SERT-siRNA at 10, 30 or
100 μg day− 1 (0.7, 2.1 or 7 nmol day− 1, respectively) during 7 days and
were killed 24 h after last administration.
FLX (Tocris, Madrid, Spain) was administered once daily at 10mg kg− 1,
intraperitoneally (i.p.), for 7 or 28 days. Mice were killed at 24 h after last
administration. Control mice received saline.
Corticosterone (Cortico, Sigma-Aldrich, Madrid, Spain) was dissolved in
commercial mineral water and brought to a pH 7.0–7.4 with HCl. Group-
housed mice were presented with Cortico solution for 28 or 49 days at:
30 μgml− 1 during 15 days (resulting in a dose of approximately 6.6 -
mg kg− 1 day− 1, p.o.), followed by 15 μgml− 1 (2.7 mg kg− 1 day− 1) during
Figure 2. Intranasal sertraline-conjugated serotonin transporter small interfering RNA (SERT-siRNA) (C-SERT-siRNA) treatment downregulates
SERT expression. Mice received intranasally: phosphate-buffered saline (PBS), sertraline-conjugated nonsense-siRNA (C-NS-siRNA) or C-SERT-
siRNA at 30 μg day− 1 (2.1 nmol day− 1) during 1, 4 or 7 days. (a) Coronal brain sections showing reduced SERT mRNA and binding site levels in
the dorsal raphe nucleus (DR) (AP coordinates: − 4.48 to − 4.72 in mm) of mice treated with C-SERT-siRNA (7-day). Scale bar: 500 μm. (b) Effects
of C-SERT-siRNA on SERT mRNA and binding site densities in the DR and median raphe nucleus (MnR) (n= 3–8 mice/group; *Po0.05,
**Po0.01, ***Po0.001 versus PBS- and C-NS-siRNA-treated mice). (c) Immunohistochemistry images showing the expression of SERT protein
(SERT-ir) in mouse DR. Bottom row are high-magniﬁcation photomicrographs of the frames in top row. Scale bars: low= 100 μm, high= 20 μm.
(d) C-SERT-siRNA treatment (7-day) decreased DR SERT protein density versus PBS- and C-NS-siRNA-treated mice (n= 3–5 mice/group;
**Po0.01). (e) Local selective serotonin reuptake inhibitor citalopram infusion by reverse-dialysis induced concentration-dependent increases
of extracellular 5-hydroxytryptamine (5-HT) in the caudate putamen (CPu) of PBS-treated mice more than in C-SERT-siRNA-treated mice (n= 7–
8 mice/group; **Po0.01 versus PBS). Data are mean± s.e.m.
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Figure 3. RNA interference-induced serotonin transporter (SERT) suppression reduces 5-hydroxytryptamine 1A (5-HT1A)-autoreceptor
expression/function and rapidly enhances the forebrain 5-HT transmission. Mice were intranasally administered with: phosphate-buffered
saline (PBS), sertraline-conjugated nonsense-small interfering RNA (siRNA) (C-NS-siRNA) or sertraline-conjugated SERT-siRNA (C-SERT-siRNA) at
30 μg day− 1 during 7-day treatment. Other groups of mice were treated with saline or ﬂuoxetine (FLX) at 10mg kg− 1 day− 1, intraperitoneally
during 7- or 28-day treatment. (a) Representative coronal brain sections showing reduced 5-HT1A receptor mRNA and binding site levels in the
dorsal raphe nucleus (DR) of C-SERT-siRNA-treated mice. Scale bar: 2 mm. (b) Effects of C-SERT-siRNA on 5-HT1A receptor mRNA and binding site
densities in the DR and median raphe nucleus (MnR) of mice (n= 3–4 mice/group; *Po0.05, **Po0.01 compared with PBS- and C-NS-siRNA-
treated mice). (c) Effects of C-SERT-siRNA and FLX on 5-HT1A-autoreceptor function. C-SERT-siRNA (7-day) decreased 5-HT1A receptor-mediated
8-OH-DPAT-stimulated [35S]GTPγS binding in the DR, whereas FLX (7-day) was without effect (n= 3–4 mice/group; **Po0.01 versus PBS- and
C-NS-siRNA-treated mice). FLX reduced 5-HT1A-autoreceptor function after 28-day treatment (n= 3–4 mice/group;
τττPo0.001 versus saline and
FLX 7-day). (d) 8-OH-DPAT did not reduce 5-HT release in the ventral hippocampus (HPCv) of C-SERT-siRNA-treated mice (7-day), unlike control
groups (n= 3–4 mice/group; **Po0.01 versus PBS and C-NS-siRNA). However, 8-OH-DPAT decreased hippocampal 5-HT concentration in saline-
and FLX-treated 7-day mice but not in 28-day FLX-treated mice (n= 5–8 mice/group; ττPo0.01 versus saline and FLX 7-day). (e) Intranasal
C-SERT-siRNA treatment increased extracellular 5-HT levels in CPu more rapidly than FLX (n= 4–10 mice/group; **Po0.01, ***Po0.001 versus
PBS and C-NS-siRNA; τPo0.05, ττPo0.01, τττPo0.001 versus saline). Signiﬁcant differences versus their respective control mice occurred after
2-day C-SERT-siRNA and after 7-day FLX treatment. Similar temporal differences were observed in HPCv (n= 3-6 mice/group; ***Po0.001 versus
PBS and C-NS-siRNA; τPo0.05, τττPo0.001 versus saline). Data are mean± s.e.m.
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3 days and 7.5 μgml− 1 (1.1 mg kg− 1 day− 1) during 10 or 31 days to allow
a gradual recovery of endogenous corticosterone plasma level.22,23 Cortico
solutions were no more than 3 days old and mantained in opaque bottles
to protect it from light. From day 21, one group of animals treated with
Cortico received daily i.n. PBS, C-NS-siRNA or C-SERT-siRNA for 7 days.
Another group of mice treated with Cortico received i.p. injections of saline
or FLX for 7 or 28 days (Supplementary Figure S1).
Plasma corticosterone levels
Posttreatment corticosterone was measured in plasma obtained from
blood samples after cardiac puncture at 1500–1600 hours using trisodium
citrate as anticoagulant. After blood centrifugation at 1000 g for 15min, all
plasma samples were stored at − 80 °C before assay by using a
commercially available kit by radioimmunoassay of 125I-labeled rat
corticosterone (Coat-A-Count, Siemens, Healthcare Diagnostics, Berkeley,
CA, USA). A gamma counter (Perkin Elmer Wallac Wizard 1470, Turku,
Finland) was used to measure radioactivity of the samples.24
In situ hybridization
Mice were killed by pentobarbital overdose, and the brains were rapidly
removed, frozen on dry ice and stored at − 80 ºC. Coronal tissue sections (14-
μm thick) were cut using a microtome-cryostat (HM500-OM, Microm,
Walldorf, Germany), thaw-mounted onto 3-aminopropyltriethoxysilane
(Sigma-Aldrich)-coated slides and kept at − 20 °C until use. Antisense
oligoprobes were complementary to bases: SERT/820-863 (GenBank
accession NM_010484.1), serotonin1A receptor-5-HT1AR/1780-1827
(NM_008308), tryptophan hydroxylase-2 (TPH2)/360-410 (NM_173391),
brain-derived neurotrophic factor (BDNF)/1188-1238 (NM_007540), vascular
endothelial growth factor (VEGF)/2217-2267 (NM_001025250), activity-
regulated cytoskeletal protein (ARC)/1990-2040 (NM_018790), TRKB recep-
tor/1075-1124 (NM_001025074), PSD-95/76-120 (D50621), and neuritin/408-
448 (NM_153529), respectively (Göttingen, Germany). Oligonucleotides were
individually labeled (2 pmol) at the 3'-end with [33P]-dATP (42500
Ci mmol−1; DuPont-NEN, Boston, MA, USA) using terminal deoxynucleotidyl-
transferase (TdT, Calbiochem, La Jolla, CA, USA). Sections were hybridized as
previously described.17,18,25 Details are shown in Supplementary Information.
Autoradiographic studies
The autoradiographic binding assays for 5-HT1AR, SERT and norepinephrine
transporter were performed using the following radioligands: (a) [3H]-8-
OH-DPAT (233 Ci mmol− 1), (b) [3H]-citalopram (70 Ci mmol− 1) and (c) [3H]-
nisoxetine (85 Ci mmol− 1), respectively (Perkin-Elmer, Madrid, Spain) as
described previously.17 The experimental conditions are summarized in
Supplementary Table S2. For 5-HT1AR-stimulated [
35S]GTPγS autoradiogra-
phy, coronal dorsal raphe nucleus (DR) sections were labeled with 0.04 nM
[35S]GTPγS.17 Details are shown in Supplementary Information.
Quantitative image analysis of ﬁlm autoradiograms
Autoradiograms were analyzed and relative optical densities (ROD) were
obtained using a computer-assisted image analyzer (MCID, Mering,
Germany). The system was calibrated with 3H- or 14C-microscales standards
to obtain fmol mg− 1 protein equivalents from ROD data. The slide
background and non-speciﬁc densities were subtracted. ROD were
evaluated in two or three adjacent sections by duplicate of each mouse
and averaged to obtain individual values. MCID system was also used to
acquire pseudocolor images. Black and white photographs were taken
from autoradiograms using a Wild 420 microscope (Leica, Heerbrugg,
Germany) equipped with Nikon DXM1200F digital camera and ACT-1
Nikon software (Soft Imaging System Gmbh, Münster, Germany). Images
were processed with Photoshop (Adobe Systems, Mountain View, CA, USA)
by using identical values for contrast and brightness.
5-Bromo-2’-deoxyuridine (BrdU) administration
BrdU was purchased from Sigma-Aldrich and dissolved in saline solution.
The last day of antidepressant treatment, mice were injected with 4 × 75 -
mg kg− 1 BrdU, i.p., every 2h and were killed 24h later in according to
Santarelli et al.11
Immunohistochemistry
Mice were anesthetized with pentobarbital and transcardially perfused
with 4% paraformaldehyde in sodium–phosphate buffer (pH 7.4). Brains
were collected, postﬁxed 24 h at 4 °C in the same solution and then placed
in gradient sucrose 10–30% for 3 days at 4 °C. After cryopreservation, serial
30-μm thick sections were cut through the olfactory bulbs, the
hippocampal formation, amygdala and the midbrain raphe nuclei.
Immunohistochemical procedure was performed for SERT, BrdU, Ki-67,
NeuroD, NeuN, Doublecortin (DCX), glial ﬁbrillary acidic protein (GFAP) and
Iba-1 using biotin-labeled antibody procedure.17 Details are shown in
Supplementary Information.
Confocal ﬂuorescence microscopy
Intracellular C-NS-siRNA distribution in 5-HT neurons was examined by
confocal microscopy using a Leica TCS SP5 laser scanning confocal
microscope (Leica Microsystems Heidelberg GmbH, Manheim, Germany)
equipped with a DMI6000 inverted microscope, blue diode (405 nm), Argon
(458/476/488/496/514), diode-pumped solid state (561 nm) and HeNe
(594/633nm) lasers. After i.n. administration with Alexa488 labeled C-NS-
siRNA at 30 μg day− 1 during 4 days, mice were killed and their brain were
extracted and processed for immunoﬂuorescence. Details are shown in
Supplementary Information.
Intracerebral microdialysis
Extracellular 5-HT concentration was measured by in vivo microdialysis as
previously described.17,18,25 Brieﬂy, one concentric dialysis probe (Cupro-
phan; 1.5-mm long) was implanted in caudate putamen (CPu; coordinates
in mm: AP, 0.5; ML, − 1.7; DV, − 4.5) or ventral hippocampus (vHPC; AP, − 3.0;
ML, − 3.0; DV, − 4.0)26 of pentobarbital-anaesthetized mice. Experiments
were performed 24–48h after surgery. To assess 8-OH-DPAT effects on
extracellular 5-HT, 1 μM SSRI citalopram (Lundbeck A/S, Valby, Copenhagen,
Denmark) was added to artiﬁcial cerebrospinal ﬂuid. Artiﬁcial cerebrospinal
ﬂuid was pumped (WPI model, SP220i) at 2.0 μl min− 1 and 30-min samples
were collected. 5-HT concentrations were analyzed by high-performance
liquid chromatography amperometric detection (+0.6V; Hewlett Packard
1049, Palo Alto, CA, USA) with 3-fmol detection limits. Baseline 5-HT levels
were calculated as the average of four predrug samples.
Figure 4. Intranasal administration of sertraline-conjugated serotonin transporter small interfering RNA (SERT-siRNA) (C-SERT-siRNA)
accelerates the proliferation of cellular precursors and dendrite complexity in the hippocampus. (a) Representative images showing an
increased number of Ki67-positive cells in the dentate gyrus (DG) of C-SERT-siRNA (7-day) or ﬂuoxetine-treated mice (FLX, 28-day) versus their
respective control mice. Bottom row shows high-magniﬁcation photomicrographs of the top row frames. Scale bars: low= 100 μm and
high= 20 μm. (b and c) Short-term C-SERT-siRNA (7-day) or long-term FLX (28-day) treatments increased similarly the number of DG Ki-67-
positive cells (n= 5–10 mice/group) and 5-bromo-2’-deoxyuridine (BrdU)-positive cells (n= 6–10 mice/group). *Po0.05, **Po0.01 versus
phosphate-buffered saline (PBS) and sertaline-conjugated nonsense-siRNA (C-NS-siRNA); τPo0.05 versus saline and FLX 7-day treatment. (d
and e) Short-term C-SERT-siRNA treatment or chronic FLX administration increased similarly the number of immature neurons identiﬁed with
NeuroD (n= 4–10 mice/group) or doublecortin (DCX; n= 5-11 mice/group) markers (*Po0.05 versus PBS and C-NS-siRNA; τPo0.05, ττPo0.01
versus saline and FLX 7-day treatment). (f) Representative images and traces from Sholl analyses of DCX-positive cells bearing a complex
dendritic morphology in the DG of mice in the different treatment group. Scale bar: 20 μm. (g) Effects of C-SERT-siRNA (7-day) or FLX (28-day)
treatments on dendritic intersection numbers and dendritic length of DCX-positive neurons (n= 4 mice/group, 5 cells/mouse; ***Po0.001
versus PBS and C-NS-siRNA; τττPo0.001 versus saline and FLX 7-day). (h) Levels of mRNA for the following genes: BDNF, VEGF, TRKB, ARC,
Neuritin, and PSD95 in the DG were analyzed by densitometry and are shown in the bar graphs (n= 3–10 mice/group; *Po0.05, ***Po0.001
versus PBS and C-NS-siRNA; τPo0.05, ττPo0.01, τττPo0.001 versus saline and FLX 7-day treatment). Values are mean± s.e.m.
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Behavioral studies
All mice were tested at 24h after treatments. All tests were performed
between 1000 and 1500 hours. Behavioral assessments were examined
with at least an interval of 1–2 days between tests. They were conducted in
the following order: (1) open ﬁeld test, (2) sucrose preference test, (3)
novelty suppressed-feeding test, and (4) tail suspension test. On test days,
animals were transported to a dimly illuminated behavioral room and were
left undisturbed for at least 1 h before testing. Behavioral tests were
conducted by an experimenter blind to mouse treatments. Details are
shown in Supplementary Information.
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Statistical analyses
All results are given as mean± s.e.m. Data were analyzed using GraphPad
Prism 6.0 (GraphPad, San Diego, CA, USA). Statistical analyses were
performed by two-tailed Student's t-test and one-way or two-way analysis
of variance followed by Tukey's post-hoc test as appropriate. In novelty
suppressed-feeding test, we used the Kaplan–Meier survival analysis due to
the lack of normal distribution of the data. Animals that did not eat during
the 10-min testing period were discarded. Mantel–Cox log-rank test was
used to evaluate differences between experimental groups, as described by
Samuels and Hen.27 Differences were considered signiﬁcant when Po0.05.
Completed statistical analyses are summarized in Supplementary Table S3.
RESULTS
Sertraline-conjugated siRNA is internalized into 5-HT neurons by
endocytosis after i.n. administration
We used a previously developed strategy of transporter-mediated
neuronal delivery of siRNA, in which the SSRI sertraline—
which selectively binds to SERT—was chemically conjugated to the
oligonucleotide.18 The working hypothesis was that the presence of
sertraline would allow the selective enrichment of this conjugated
siRNA in 5-HT neurons, where the targeted transporter (SERT) is
differentially expressed.28 As ﬁrst evidence in support of this
mechanism, we previously showed that sertraline pretreatment
(20mg kg− 1, i.p.) prevented the effects of sertraline-conjugated
siRNA, indicating that conjugated siRNA molecules enter 5-HT
neurons via SERT.18
For localization purposes, we synthesized an alexa488-labeled
sertraline-conjugated nonsense-siRNA (A488-C-NS-siRNA). Confocal
ﬂuorescence microscopy revealed that A488-C-NS-siRNA was
intracellularly detected in TPH2-positive midbrain 5-HT neurons
after i.n. administration (Figure 1a). Confocal analysis showed that
A488-C-NS-siRNA molecules were more efﬁciently uptaken by TPH2-
positive neurons in the DR than in median raphe nucleus (MnR)
(Figures 1b and d and Supplementary Figure S2). In addition, A488-
C-NS-siRNA was absent in cells of brain areas close to the
application site (olfactory bulbs) or to brain ventricles (hippocam-
pus) (Supplementary Figure S3), supporting that surface SERT
expression is a requirement for oligonucleotide uptake and
internalization. Sertraline-conjugated siRNA was possibly accumu-
lated in 5-HT cells perhaps by endocytosis and entered in a complex
network of trafﬁcking pathways as vesicles containing A488-C-NS-
siRNA co-localized with Rab5 (early endosome marker) and Rab7
(late endosome marker) (Supplementary Figure S4). Further studies
are needed to fully characterize the route used by sertraline-
conjugated siRNA molecules to reach raphe 5-HT neurons.
Sertraline-conjugated SERT-siRNA induces selective and safe
suppression of SERT expression
We ﬁrst examined the effect of i.n. C-SERT-siRNA administration
(30 μg day− 1) on SERT expression. SERT mRNA and binding site
levels were signiﬁcantly lower in the raphe nuclei of C-SERT-siRNA-
treated mice compared with control groups (PBS- and C-NS-siRNA-
treated mice), with a maximal reduction after 7-day treatment.
Immunohistochemistry analysis conﬁrmed these results at the
protein level (Figures 2a and d and Supplementary Figure S5).
C-SERT-siRNA suppressed SERT expression more markedly in the
DR than in MnR, as supported by the higher intracellular density of
oligonucleotide in DR 5-HT neurons (Figure 1). We then evaluated
the dose-related effects of C-SERT-siRNA (10–30–100 μg day− 1
during 7 days, i.n.) on SERT expression in the DR. All doses
signiﬁcantly decreased SERT mRNA expression 24 h after last
administration, with no signiﬁcant differences between doses,
despite a slightly greater reduction at 30 and 100 μg day− 1
(Supplementary Figure S6). Next we assessed the temporal pattern
of SERT decrease. For this purpose, mice were i.n. administered
with C-SERT-siRNA at 30 μg day− 1 during 7 days and killed at
different times after last administration. SERT mRNA level in the
DR was signiﬁcantly lower in C-SERT-siRNA-treated mice that in
the control group at 1 and 3 days postadministration, with a
recovery of SERT expression to control values at 7 and 15 days
postadministration (Supplementary Figure S7). These values agree
with data in the literature indicating a short half-life of SERT.19
The reduced SERT expression was accompanied by a decreased
function, as assessed by intracerebral microdialysis in the CPu,
a DR-innervated area. Hence, i.n. C-SERT-siRNA treatment
(30 μg day−1, 7-day) doubled basal extracellular 5-HT levels in the
CPu versus PBS-treated mice (9.9± 1.6 and 4.7± 0.7 fmol fraction− 1,
respectively; n=7-8; Po0.01) and provoked a lesser response of
the SSRI citalopram to increase extracellular 5-HT (Figure 2e).
C-SERT-siRNA (30 μg day− 1, 7-day, i.n.) did not induce neuronal
degeneration (NeuN-positive), astrogliosis (GFAP-positive) nor
immune responses (Iba-1-positive) (Supplementary Figure S8).
Similarly, 7-day C-SERT-siRNA did not alter TPH2 mRNA levels in
5-HT neurons nor the binding density of [3H]-nisoxetine, which
recognizes norepinephrine transporter (Supplementary Figure S9).
Altogether, these data support the speciﬁcity and safety of
C-SERT-siRNA effects.
RNAi-based SERT suppression rapidly attenuates
5-HT1A-autoreceptor expression/function and enhances
forebrain 5-HT transmission
Concurrently, 7-day C-SERT-siRNA treatment reduced 5-HT1A-
autoreceptor expression and function in mouse (Figures 3a
and d), as also described after DR infusion of a unmodiﬁed
SERT-siRNA in mouse or SERT antisense-plasmid in rat.17,19 C-SERT-
siRNA diminished 5-HT1A-autoreceptor mRNA level in the DR at
both doses tested (30 and 100 μg day− 1), but not 10 μg day− 1,
24 h after last siRNA administration (Supplementary Figures S10a
and b). Decreased 5-HT1A-autoreceptor response is necessary for
the clinical antidepressant action, as 5-HT1A-autoreceptor activa-
tion by the excess 5-HT produced by SSRI/SNRI in the DR reduces
Figure 5. Short-term intranasal (i.n.) treatment with sertraline-conjugated serotonin transporter small interfering RNA (SERT-siRNA) (C-SERT-
siRNA) efﬁciently attenuates the behavioral deﬁcits in a stress-induced depression model. Grouped-housed male C57BL/6J mice were
presented during 28 or 49 days with vehicle (non-stressed mice) or corticosterone (stressed mice) in the presence or absence of an
antidepressant treatment (C-SERT-siRNA 30 μg day− 1, i.n. or ﬂuoxetine (FLX) 10mg kg− 1 day− 1, intraperitoneally) during the last 7 or 28 days
of the corticosterone regimen. (a and b) Short-term C-SERT-siRNA reversed the reduction of sucrose intake and preference in the
corticosterone-induced anhedonia (n= 10–16 mice/group; ***Po0.001 versus non-stressed mice; ^^^Po0.001 versus corticosterone-
stressed mice treated with phosphate-buffered saline (PBS) or sertraline-conjugated nonsense-siRNA (C-NS-siRNA)). FLX induced a similar
recovery after 28-day, but not after 7-day, treatment (n= 7–12 mice/group; τττP o0.001 versus non-stressed mice; ^^^Po0.001 versus
corticosterone-stressed mice treated with saline. (c) Effect on novelty suppressed feeding test (NSFT). Seven-day C-SERT-siRNA, but not 7-day
FLX, reversed the increased latency to feed in corticosterone-treated mice (n= 8–12 mice/group; **Po0.01 versus non-stressed mice;
^Po0.05 versus corticosterone-stressed mice treated with PBS or C-NS-siRNA). Similar effects were elicited by 28-day FLX administration
(n= 7–12 mice/group; ττPo0.01 versus non-stressed mice; ^Po0.05 versus corticosterone-stressed mice treated with saline). (d) Survival
analysis of NSFT data. (e) C-SERT-siRNA (7-day) or FLX (28-day), but not FLX 7-day, decreased the immobility time in the tail suspension test
(TST) in cortico-stressed mice (n= 8–15 mice/group). **Po0.01, ***Po0.001, τPo0.05, ττPo0.01 versus their non-stressed mice, respectively;
^Po0.05, ^^Po0.01 versus cortico-stressed mice treated with saline, PBS or C-NS-siRNA, respectively. Values are mean± s.e.m.
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5-HT neuronal activity and 5-HT release, thus counteracting the
facilitation of 5-HT transmission induced by SERT blockade.29–31
This inhibitory feedback is an essential component of the
delayed therapeutic action of antidepressant drugs. Long-term
FLX treatment (10 mg kg− 1, 28-day, but not 7-day, i.p.) attenuated
5-HT1A-autoreceptor-mediated activation of G-proteins as
expected32 and prevented the effect of 8-OH-DPAT (selective
5-HT1A receptor agonist) to reduce hippocampal 5-HT release. In
contrast, 7-day C-SERT-siRNA administration (30 μg day− 1) was
sufﬁcient to downregulate 5-HT1A-autoreceptors and to avoid the
8-OH-DPAT effect on 5-HT release (Figures 3c and d). Neither
treatment modiﬁed the hippocampal [35S]GTP-γ-S binding in the
presence of 8-OH-DPAT (Supplementary Figure S10c). The
reduction in SERT expression/function, together with the 5-HT1A-
autoreceptor downregulation, increased extracellular 5-HT con-
centration in the CPu and hippocampus more rapidly and
markedly than after FLX (Figure 3e). The present results indicate
that cellular changes—classically associated to long-term SSRI
treatment—can be achieved after only 1 week of i.n. C-SERT-siRNA
administration. These observations suggest that SSRI and C-SERT-
siRNA distinctly regulate the molecular mechanisms controlling
SERT function, resulting in a more rapid and efﬁcient increase of
presynaptic 5-Ht function with the RNAi strategy.
Sertraline-conjugated SERT-siRNA rapidly increases and facilitates
maturation of newborn cells
The clinical antidepressant action is also associated with neural
stem cell proliferation, neurogenesis and the establishment of
new synaptic contacts in brain circuits controlling motivation,
emotion and cognition.33,34 Treatments with C-SERT-siRNA (30 -
μg day− 1, 7-day) or FLX (10 mg kg− 1, 28-day, but not 7-day)
markedly increased the number of Ki67- and BrdU-labeled
progenitor cells in the dentate gyrus of hippocampus (Figures
4a–c, Supplementary Figure S11a, Supplementary Table S4). In
addition, 7-day C-SERT-siRNA promoted signiﬁcantly the genera-
tion of NeuroD- and DCX-expressing neurons faster than FLX (28-
day) (Figures 4d and e, Supplementary Figure S11b,
Supplementary Table S4). Dendritic morphology of newborn cells
was comparable after 7-day C-SERT-siRNA and 28-day FLX
treatments, as indicated by Sholl analysis on DCX-positive neurons
with tertiary dendrites, the number of intersections and dendrite
length (Figures 4f and g). These data support that RNAi-induced
SERT knockdown rapidly enhances neuronal plasticity in hippo-
campus as a result of the increased 5-HT signaling.
These cellular changes were accompanied by a higher
activation of neuroplasticity-associated genes in the hippocam-
pus. Seven-day C-SERT-siRNA or 28-day FLX treatments increased
comparably the expression of BDNF and its TRKB receptor as well
as VEGF and ARC essentially in the dentate gyrus (Figure 4h and
Supplementary Figure S12). Likewise, mRNA neuritin and PSD95
levels, two critical downstream mediators of antidepressant/BDNF-
induced plasticity35–37 were selectively increased in the dentate
gyrus of both the mice groups. However, a 7-day FLX regime was
without effect on these variables (Figure 4).
Short-term sertraline-conjugated SERT-siRNA efﬁciently attenuates
the behavioral alterations in the corticosterone depression model
Finally, we conﬁrmed the potential therapeutic beneﬁt of the
RNAi-induced downregulation of SERT expression in a stress-
related model of depression: the corticosterone model—a well-
established stress inducer.12,22 Despite displaying plasma corti-
costerone levels and open ﬁeld behavior similar to controls, mice
exposed to a low oral dosage of corticosterone for 28 or 49 days
showed a persistent depressive-like behavior, characterized by
reduced sucrose preference, increased latency in the novelty
suppressed feeding paradigm and increased immobility time in
the tail suspension test (Supplementary Figure S13). These
depressive-like behaviors were reversed to the same extent
by 7-day i.n. C-SERT-siRNA (30 μg day− 1) and by 28-day FLX
(10 mg kg− 1) treatments (Figure 5). In contrast, 7-day FLX did not
evoke any antidepressant-like effects.
DISCUSSION
Here we show that C-SERT-siRNA evokes very fast (7-day) and robust
antidepressant-like responses in control and corticosterone-treated
mice, comparable than those evoked by a 28-day FLX treatment.
Prior studies using RNAi strategies to elicit antidepressant-like
responses in rodents used unmodiﬁed siRNA sequences directed
against SERT or 5-HT1A receptors.
16,17,25 The study conﬁrms and
extends our previous observations on the use of sertraline-
conjugated siRNA sequences to silence genes in 5-HT neurons.18
The design of the conjugated siRNA allows its selective enrichment
in 5-HT neurons after i.n. administration, opening new ways for the
therapeutic use of RNAi strategies to treat mood disorders, which
may overcome the limitations of standard antidepressant treat-
ments, that is, slow clinical action and low efﬁcacy.
As a consequence of the fast and effective SERT down-
regulation, 7-day C-SERT-siRNA treatment (i) reduced 5-HT1A-
autoreceptor expression/function, (ii) facilitated forebrain
serotonin neurotransmission, (iii) accelerated the proliferation of
neuronal precursors, (iv) increased the expression of growth
factors (for example, BDNF, VEGF) and genes promoting neurite
outgrowth (for example, neuritin, PSD95) and (v) increased
hippocampal dendritic complexity and synaptic plasticity. All
these variables are predictive of clinical antidepressant action.
In addition, short-term C-SERT-siRNA treatment normalized
stress-induced depressive-like behaviors, which were only sensi-
tive to 28-day FLX treatment. Interestingly, the above actions
were produced by the i.n. administration of very small doses
(2.1 nmol day− 1) of C-SERT-siRNA illustrating the effectiveness of
the present RNAi strategy.
The precise mechanism(s) used by C-SERT-siRNA reach 5-HT
neurons are not fully understood. Unlike other strategies used for
oligonucleotide delivery to target neuronal populations,38,39 here
we used a transporter (SERT)-mediated process to target a
selective gene (SERT) expressed in 5-HT neurons, as previously
used to silence 5-HT1A-autoreceptors.
18 Paradoxically, this
approach could limit the extent of the intracellular C-SERT-siRNA
accumulation, as the conjugated siRNA enters 5-HT neurons via
SERT.18 However, the present results indicate that the remaining
expression of SERT—even after 7-day C-SERT-siRNA treatment—is
sufﬁcient to evoke a very large increase of presynaptic serotoner-
gic function.
Moreover, as trans-nasal oligonucleotide delivery to brain is
mediated by extracellular mechanisms,40–42 it is also possible that
C-SERT-siRNA can use this extracellular pathway before being
taken up by serotonergic terminals and transported back to cell
bodies in the midbrain. This view is showed by the association of
the conjugated siRNA to Rab7, supporting trafﬁc via late
endomembrane compartments.
The present results indicate that C-SERT-siRNA is preferentially
accumulated into DR (versus MnR) 5-HT neurons. Anatomical and
functional differences between the two 5-HT subsystems have been
reported.43–45 In particular, SERT expression is greater in DR than in
MnR and DR-innervated areas are more sensitive to the action of
SSRI,40 which suggests a preferential uptake of C-SERT-siRNA by
DR axons.
Consistent with previous ﬁndings using intra-raphe SERT-siRNA
infusion,17 i.n. C-SERT-siRNA treatment triggered a complex
cascade of signaling events that ultimately results in down-
regulation of SERT and also 5-HT1A-autoreceptors on midbrain
serotonin neurons. As both mechanisms tightly control the active
5-HT fraction, their downregulation by C-SERT-siRNA dramatically
increased the extracellular 5-HT levels in the forebrain in a faster
Intranasal delivery of conjugated SERT-siRNA
A Ferrés-Coy et al
336
Molecular Psychiatry (2016), 328 – 338 © 2016 Macmillan Publishers Limited
way than that produced by the pharmacological SERT blockade
with FLX. The intracellular mechanisms by which short-term
C-SERT-siRNA or chronic SSRI treatments downregulate SERT and
5-HT1A receptor levels to increase the serotonergic neurotransmis-
sion are still poorly known. Recent reports suggest a role for
altered patterns of gene expression in mediating the long-term
therapeutic effects of SSRIs, focusing on the potential involvement
of microRNAs as ﬁne-tuners and on–off switches of gene
expression.15,46 Hence, miR-135 levels were upregulated after
single and chronic FLX administrations,47 suggesting that this
microRNA may act as an endogenous homeostatic mechanism to
maintain the physiological balance between SERT and 5-HT1A-
autoreceptors.
Similarly to intra-raphe SERT-siRNA application,17 the short-term
i.n. administration of C-SERT-siRNA—but not FLX—evoked hippo-
campal postsynaptic responses to the enhanced serotonergic
signaling, which are predictive of clinical antidepressant effects.
These responses included the proliferation of progenitor cells,
stimulation of dendritic branching, acceleration of the maturation
of immature DCX neurons and increased expression of spine/
synapse markers. Moreover, these postsynaptic changes were
accompanied by the reversal of the behavioral deﬁcits caused by
prolonged corticosterone exposure. The C-SERT-siRNA ability to
increase synaptic plasticity may be mediated by an enhancement
of BDNF/TRKB signaling, among others that were upregulated
after 7-day C-SERT-siRNA treatment. Activation of their down-
stream signaling pathways was shown to enhance maturation and
dendritic development.48 Induction of neuritin and PSD95 are also
indicative of an increased synapse formation and function.37
However, additional antidepressant mechanisms may be involved,
resulting from the enhanced 5-HT neurotransmission in other
brain areas implicated in MDD, such as the ventromedial
prefrontal cortex.
In conclusion, our ﬁndings indicate that RNAi-based SERT
repression elicits faster and more effective antidepressant-like
actions than persistent SERT blockade with FLX. Enhancing
serotonin signaling through downregulation of SERT expression
evokes standard antidepressant responses, promotes the genera-
tion of new hippocampal neurons, increases synaptic plasticity
and counteracts behavioral deﬁcits in a stress-induced depression
model. Furthermore, the study has a high translational value due
to the use of a clinically feasible (i.n.) administration route.40–42
This opens new therapeutic perspectives for the treatment of
mood disorders, including MDD.
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